Koneksa’s Post

Our recent study presented during NASH Tag 2024, aims to retrospectively compare the efficacy of two combinations in one-step approach with two biomarkers, LiverSTAT and LSM (Liver Stiffness Measurement) versus FIB-4 and LSM for the identification of advanced fibrosis (F3F4) in a multicenter-multiethnic dataset of MASLD patients. The study demonstrated the one-step assessment of MASLD-related fibrosis using the combination LiverSTAT and Fibroscan: • Correctly identified twice as many F3F4 patients than the combination of FIB-4 and Fibroscan • Does not miss F3F4 patients because of a “grey zone” • Moreover, can help to detect 41% of F3F4 missed cases by FIB-4 “grey zone” • Had a high concordance rate to rule in/out advanced fibrosis and, therefore, can work as an upfront screening for F3F4 before referral to more complex assessments Find out more: https://lnkd.in/gyD2QEpp #LIVERSTAT #fibrostudies #MASLD

Naresh Bumma, The Ohio State University, Columbus, US, presented on BCMA-directed bispecific antibodies during the Multiple Myeloma Hub’s recent symposium. Some of the latest data from the EHA, ASCO, and ASH congresses were explored, with a focus on differences between agents and biomarkers of response. Bumma then discussed the integration of BCMA-directed antibodies into the current #MultipleMyeloma landscape, finishing with a real case example to emphasize their applicability to clinical practice. “We need to consider patient-specific clinical factors. Access is very important, and obviously patient preference is very important” Click the link below to catch up 👇 https://loom.ly/3ZEBvZE #bispecific #myeloma #mmsm

The SMCxPRO® platform is an ultrasensitive #immunoassay platform that can detect low levels of established disease biomarkers, capturing extremely small concentrations. As a result, this platform can monitor small changes in #proteinconcentrations to accurately measure #biomarkers associated with #disease progression for research purposes. Click to watch the video and learn how to unlock femtogram/mL biomarker quantification in your lab!

The SMCxPRO® platform is an ultrasensitive #immunoassay platform that can detect low levels of established disease biomarkers, capturing extremely small concentrations. As a result, this platform can monitor small changes in #proteinconcentrations to accurately measure #biomarkers associated with #disease progression for research purposes. Click to watch the video and learn how to unlock femtogram/mL biomarker quantification in your lab!

The SMCxPRO® platform is an ultrasensitive #immunoassay platform that can detect low levels of established disease biomarkers, capturing extremely small concentrations. As a result, this platform can monitor small changes in #proteinconcentrations to accurately measure #biomarkers associated with #disease progression for research purposes. Click to watch the video and learn how to unlock femtogram/mL biomarker quantification in your lab!

The SMCxPRO® platform is an ultrasensitive #immunoassay platform that can detect low levels of established disease biomarkers, capturing extremely small concentrations. As a result, this platform can monitor small changes in #proteinconcentrations to accurately measure #biomarkers associated with #disease progression for research purposes. Click to watch the video and learn how to unlock femtogram/mL biomarker quantification in your lab!

The SMCxPRO® platform is an ultrasensitive #immunoassay platform that can detect low levels of established disease biomarkers, capturing extremely small concentrations. As a result, this platform can monitor small changes in #proteinconcentrations to accurately measure #biomarkers associated with #disease progression for research purposes. Click to watch the video and learn how to unlock femtogram/mL biomarker quantification in your lab!

The SMCxPRO® platform is an ultrasensitive #immunoassay platform that can detect low levels of established disease biomarkers, capturing extremely small concentrations. As a result, this platform can monitor small changes in #proteinconcentrations to accurately measure #biomarkers associated with #disease progression for research purposes. Click to watch the video and learn how to unlock femtogram/mL biomarker quantification in your lab!

Please see our latest press release update on DMD and DM1

The SMCxPRO® platform is an ultrasensitive #immunoassay platform that can detect low levels of established disease biomarkers, capturing extremely small concentrations. As a result, this platform can monitor small changes in #proteinconcentrations to accurately measure #biomarkers associated with #disease progression for research purposes. Click to watch the video and learn how to unlock femtogram/mL biomarker quantification in your lab! https://lnkd.in/ehVxsvpk